Clinical applications of mesenchymal stem cells in chronic lung diseases

被引：33

作者：

Antoniou, Katerina M. ^{[1
,2
]}

Karagiannis, Konstantinos ^{[1
,2
]}

Tsitoura, Eliza ^{[1
]}

Bibaki, Eleni ^{[1
,2
]}

Lasithiotaki, Ismini ^{[1
,2
]}

Proklou, Athanasia ^{[1
,2
]}

Spandidos, Demetrios A. ^{[3
]}

Tzanakis, Nikos ^{[2
]}

机构：

[1] Univ Crete, Sch Med, Lab Mol & Cellular Pneumonol, Iraklion 71110, Greece

[2] Univ Crete, Univ Hosp, Dept Thorac Med, Interstitial Lung Dis Unit, Iraklion 71110, Greece

[3] Univ Crete, Sch Med, Lab Clin Virol, Iraklion 71003, Greece

来源：

BIOMEDICAL REPORTS | 2018年 / 8卷 / 04期

关键词：

mesenchymal stem cells; lung; idiopathic pulmonary fibrosis; acute respiratory distress syndrome; chronic obstructive pulmonary disease;

D O I：

10.3892/br.2018.1067

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair in vivo. The therapeutic potential of ex vivo expanded MSCs are currently under investigation for a variety of chronic and acute lung diseases. This review summarizes the encouraging results regarding the safety of MSCs administration from recent and current clinical trials for idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and chronic obstructive pulmonary disease. It also reviews the early preliminary data extracted by the same trials regarding the efficacy of MSCs in the aforementioned lung diseases.

引用

页码：314 / 318

页数：5

共 34 条

[1]

Baughman RP, 2015, SARCOIDOSIS VASC DIF, V32, P106

[2] A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis [J].